Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics
- PMID: 15637527
- DOI: 10.1016/j.clpt.2004.08.026
Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics
Abstract
Objective: Fexofenadine is a substrate of P-glycoprotein and organic anion transporting polypeptides. The aim of this study was to compare the inhibitory effects of different transporting inhibitors on fexofenadine pharmacokinetics.
Methods: Twelve male volunteers took a single oral 120-mg dose of fexofenadine. Thereafter three 6-day courses of either 240 mg verapamil, an inhibitor of P-glycoprotein, 800 mg cimetidine, an inhibitor of organic cation transporters, or 2000 mg probenecid, an inhibitor of organic anion transporting polypeptides, were administered on a daily basis in a randomized fashion with the same dose of fexofenadine on day 6. Plasma and urine concentrations of fexofenadine were monitored up to 48 hours after dosing.
Results: Verapamil treatment significantly increased the peak plasma concentration by 2.9-fold (95% confidence interval [CI], 2.4- to 4.0-fold) and the area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of fexofenadine by 2.5-fold (95% CI, 2.0- to 3.3-fold). No changes in any plasma pharmacokinetic parameters of fexofenadine were found during cimetidine treatment. AUC(0-infinity) was slightly but significantly increased during probenecid treatment by 1.5-fold (95% CI, 1.1- to 2.4-fold). Renal clearance of fexofenadine was significantly decreased during cimetidine treatment to 61% (95% CI, 50%-98%) and during probenecid treatment to 27% (95% CI, 20%-58%) but not during verapamil treatment.
Conclusion: This study suggests that verapamil increases fexofenadine exposure probably because of an increase in bioavailability through P-glycoprotein inhibition and that probenecid slightly increases the area under the plasma concentration-time curve of fexofenadine as a result of a pronounced reduction in renal clearance. However, it may be difficult to explain these interactions by simple inhibitory mechanisms on target transporters.
Similar articles
-
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.Clin Pharmacol Ther. 2006 Mar;79(3):218-30. doi: 10.1016/j.clpt.2005.11.001. Epub 2006 Feb 7. Clin Pharmacol Ther. 2006. PMID: 16513446 Clinical Trial.
-
Time-dependent interaction between lopinavir/ritonavir and fexofenadine.J Clin Pharmacol. 2006 Jul;46(7):758-67. doi: 10.1177/0091270006288733. J Clin Pharmacol. 2006. PMID: 16809801 Clinical Trial.
-
Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.Clin Pharmacol Ther. 2005 Mar;77(3):170-7. doi: 10.1016/j.clpt.2004.10.005. Clin Pharmacol Ther. 2005. PMID: 15735611 Clinical Trial.
-
Clinical pharmacokinetics of fexofenadine enantiomers.Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615. Expert Opin Drug Metab Toxicol. 2010. PMID: 19947891 Review.
-
Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.Fundam Clin Pharmacol. 2004 Aug;18(4):399-411. doi: 10.1111/j.1472-8206.2004.00254.x. Fundam Clin Pharmacol. 2004. PMID: 15312146 Review.
Cited by
-
Non-Nutritive Sweeteners Acesulfame Potassium and Sucralose Are Competitive Inhibitors of the Human P-glycoprotein/Multidrug Resistance Protein 1 (PGP/MDR1).Nutrients. 2023 Feb 23;15(5):1118. doi: 10.3390/nu15051118. Nutrients. 2023. PMID: 36904118 Free PMC article.
-
Kidney Drug Transporters in Pharmacotherapy.Int J Mol Sci. 2023 Feb 2;24(3):2856. doi: 10.3390/ijms24032856. Int J Mol Sci. 2023. PMID: 36769175 Free PMC article. Review.
-
Does Ethnic Variability Exist in the Systemic Exposures of OATP1A2 Substrates-Fexofenadine in Taiwanese?Indian J Pharm Sci. 2015 Sep-Oct;77(5):573-8. doi: 10.4103/0250-474x.169032. Indian J Pharm Sci. 2015. PMID: 26798172 Free PMC article.
-
Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects.Br J Clin Pharmacol. 2013 Apr;75(4):1053-62. doi: 10.1111/j.1365-2125.2012.04453.x. Br J Clin Pharmacol. 2013. PMID: 22946890 Free PMC article. Clinical Trial.
-
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.Clin Pharmacol Ther. 2008 Oct;84(4):506-12. doi: 10.1038/clpt.2008.102. Clin Pharmacol Ther. 2008. PMID: 19238656 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources